Paper Details

  1. Home
  2. Paper Details

Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity.

Author: BergerMartin R, GeorgievKaloyan D, KonstantinovSpiro M, PilichevaBissera A, TodorovPlamen T, YosifovDeyan Y, ZaharievaMaya M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Erufosine, an alkylphosphocholine, demonstrated significant cytotoxic activity against multiple myeloma (MM) cell lines, with a complex mode of action involving both apoptotic and non-apoptotic mechanisms. It showed synergistic interactions with other drugs, inhibited cell migration, and was not toxic to normal hematopoietic progenitor cells (HPCs).
Paper Details　
Original Abstract of the Article :
PURPOSE: Erufosine is an i.v. injectable alkylphosphocholine which is active against various haematological malignancies in vitro. In the present study, its effects on multiple myeloma (MM) cell lines and on murine and human hematopoietic progenitor cells (HPCs) were investigated. METHODS: The foll...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00280-010-1273-5

データ提供：米国国立医学図書館（NLM）

Erufosine: A New Oasis in the Desert of Multiple Myeloma

This research ventures into the challenging landscape of multiple myeloma, a type of blood cancer. It's like exploring a vast desert where we're searching for a new weapon to fight this disease. The researchers studied the potential of erufosine, a drug already known for its effectiveness against other types of blood cancers, to combat multiple myeloma. Their findings suggest that erufosine could be a valuable weapon in the fight against this cancer, offering a potential oasis of hope for patients.

Erufosine: A Promising New Antimyeloma Drug

The research shows that erufosine is effective against multiple myeloma cell lines, without harming healthy blood cells. This is a significant finding, suggesting that erufosine could be a safe and effective treatment option for patients. It's a potential breakthrough in the fight against this devastating disease.

Finding Hope in the Desert of Cancer

This study brings a glimmer of hope to those battling multiple myeloma. It highlights the potential of erufosine to effectively target cancer cells while sparing healthy ones. It reminds us that even in the seemingly endless desert of cancer, new oases of hope can emerge.

Dr. Camel's Conclusion

This research explores erufosine as a potential weapon against multiple myeloma. Its effectiveness against myeloma cell lines, combined with its safety for healthy cells, makes it a promising candidate for further development and clinical trials. It's a promising oasis in the desert of cancer research, potentially offering a new hope for patients.
Date :
  1. Date Completed 2011-01-31
  2. Date Revised 2012-11-15
Further Info :

Pubmed ID

20177898

DOI: Digital Object Identifier

10.1007/s00280-010-1273-5

Related Literature

Article Analysis
・Effects of bendamustine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.